The United Kingdom and the United States have signed a important commercial pact that will keep zero import taxes on British pharmaceutical products going into the US market.
The Terms of the Pact
As part of the deal, the UK has agreed to raise spending on drugs through the National Health Service (NHS). This move guarantees that import taxes on these crucial exports will be held at zero for a period of the next three years.
This development comes after recent statements to hike duties on branded drug imports, with increases discussed reaching double the cost.
"This agreement with the United Kingdom bolsters the global environment for new treatments and introduces long-overdue equity to transatlantic drug exports," an announcement noted.
Commercial Importance
Pharmaceuticals represent one of the Britain's largest export categories to the US, which is clearly the biggest market for leading British pharmaceutical firms.
Trade data indicate that in the one-year period leading up to September, the UK sold drugs worth £11.1bn to the US. This value accounted for nearly one-fifth of total UK exports in that timeframe.
"This guarantee safeguards jobs, increases capital expenditure and facilitates the UK to establish itself as a worldwide center for medical research," a government official remarked.
Detailed UK Commitments
The agreement includes several key pledges from the UK:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it deems new treatments to be prohibitively costly by 25%.
- Increased NHS Spending: There is a goal to double total health service expenditure on treatments from 0.3 percent of GDP to 0.6% over the next decade.
- Payback Limit: The sum drug companies must refund to the NHS to stay within budget will be capped at 15%. Previously, refunds topped 20%.
Industry Background
This agreement follows a protracted tension between the sector and the ministers over medicine costs and approval rates.
This friction were exacerbated by assertions that US customers were charged significantly more for the equivalent treatments than patients in the UK and Europe.
Recently, several large manufacturing plans in the UK have been paused or abandoned, while substantial expansions have been directed toward American operations.
One official publicly accepted that the NHS must spend more on drugs, noting that its expenditure on drugs had declined as a proportion of its overall budget over the past decade.
